In the first half of 2026, record-setting cross-border licensing deals propelled some Chinese biotech companies to profitability, offsetting previous losses. However, with multinational drugmakers indicating plans to moderate business development budgets, questions arise about the future sustainability of relying heavily on out-licensing income.
- Chinese biotech cross-border deals hit a record $110 billion in H1 2026
- Out-licensing income overtakes IPOs as prime funding source
- Multinational drugmakers signal more cautious acquisition spending
What happened
Chinese biotechnology companies experienced a remarkable turnaround in the first half of 2026 driven primarily by record-breaking cross-border licensing deals with large global pharmaceutical firms. These agreements provided significant upfront payments and milestone fees, enabling previously loss-making firms such as RemeGen, CSPC Innovation Pharmaceutical, and Suzhou Zelgen Biopharmaceuticals to report substantial profits. The total value of cross-border deals for innovative drugs reached approximately $110 billion, representing most of the year’s deal activity by mid-year and vastly exceeding funding raised from initial public offerings and pre-IPO financings in China.
Why it matters
The surge in cross-border deals signals a shift in how Chinese biotech companies finance their growth and development, reflecting rising global demand for innovative drug candidates sourced from China. Compared to global peers, Chinese biotech assets are perceived as cost-effective and capable of rapid data generation, boosting their attractiveness amid global pharmaceutical companies’ rising cost constraints. This trend underscores China’s growing importance as a contributor to global drug pipelines and innovation ecosystems.
However, multinational pharmaceutical executives have recently indicated increased caution in their business development spending, emphasizing more disciplined deal-making strategies. Companies such as AstraZeneca and Pfizer have noted they have largely placed their major bets already, suggesting a potential slowdown in large-scale acquisitions. This emerging conservative stance introduces uncertainty about whether Chinese biotech firms can sustain their momentum solely through out-licensing revenues or if more diverse financing approaches will be required.
What to watch next
Market observers and industry analysts will closely monitor the ongoing appetite of multinational drugmakers for licensing assets from Chinese biotech companies. While small to medium deals and licensing arrangements are expected to continue given their cost efficiency, the possibility of a broader slowdown or more selective deal-making by global pharmaceutical players could impact funding flow and valuations within the sector. The magnitude of out-licensing activity through the full year of 2026 remains a key indicator of China’s biotech financial health.